These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 11057884

  • 1. Reactivation of chronic hepatitis C virus infection by immunoadsorption in factor VIII inhibitor haemophilia.
    Rommel F, Toepfer M, Eberle J, Schiffl H, Spannagl M, Schramm W.
    Thromb Haemost; 2000 Oct; 84(4):733-4. PubMed ID: 11057884
    [No Abstract] [Full Text] [Related]

  • 2. A multicentre prospective cohort study of immune function in patients treated with monoclonally immunopurified or resin-purified SNBTS high-potency factor VIII concentrate.
    Hay CR.
    Transfus Sci; 1996 Sep; 17(3):337-8. PubMed ID: 10184610
    [No Abstract] [Full Text] [Related]

  • 3. Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor?
    Yee TT, Lee CA.
    Thromb Haemost; 1999 May; 81(5):852. PubMed ID: 10365768
    [No Abstract] [Full Text] [Related]

  • 4. Inhibitor development in a multitransfused patient with severe haemophilia A.
    van den Berg HM, Roosendaal G, Voorberg J, Mauser-Bunschoten EP.
    Thromb Haemost; 1999 Jul; 82(1):151-2. PubMed ID: 10456472
    [No Abstract] [Full Text] [Related]

  • 5. Prevalence of factor VIII inhibitors in patients with hemophilia A in Brazil.
    Rieger A, Roisenberg I.
    Thromb Haemost; 1999 Mar; 81(3):475-6. PubMed ID: 10102489
    [No Abstract] [Full Text] [Related]

  • 6. Use of factor VIII after inhibitor clearance in patients with moderate haemophilia A: a case series.
    Tran DQ, Harvey RD, Meeks SL, Chapman R, Kempton CL.
    Haemophilia; 2014 Jul; 20(4):e344-6. PubMed ID: 24750497
    [No Abstract] [Full Text] [Related]

  • 7. Circulating antibodies in factor VIII deficiency hemophilia: report of case.
    Cudzinowski L.
    ASDC J Dent Child; 1979 Jul; 46(1):54-6. PubMed ID: 283081
    [No Abstract] [Full Text] [Related]

  • 8. Acquired haemophilia in a patient treated with interferon-α for hepatitis C infection.
    Goyal J, Tyagi P, Kumar N.
    Haemophilia; 2012 May; 18(3):e73-4. PubMed ID: 22404644
    [No Abstract] [Full Text] [Related]

  • 9. Factor VIII inhibitory antibody in a patient with combined factor V/factor VIII deficiency.
    Buckner TW, Nielsen BI, Key NS, Ma A.
    Haemophilia; 2015 Jan; 21(1):e77-80. PubMed ID: 25472918
    [No Abstract] [Full Text] [Related]

  • 10. Treatment of mantle cell lymphoma with autologous stem-cell transplantation in a patient with severe congenital haemophilia-A and chronic (B and C virus) hepatitis.
    Rejto L, Schlammadinger A, Ilonczai P, Tornai I, Batar P, Remenyi G, Kiss A, Udvardy M.
    Haemophilia; 2010 Jul 01; 16(4):706-7. PubMed ID: 20398068
    [No Abstract] [Full Text] [Related]

  • 11. Suggestions for the management of factor VIII inhibitors.
    Rubinger M, Rivard GE, Teitel J, Walker H, Inhibitor Subcommittee of the Association of Hemophilia Clinic Directors of Canada.
    Haemophilia; 2000 Jul 01; 6 Suppl 1():52-9. PubMed ID: 10982269
    [No Abstract] [Full Text] [Related]

  • 12. [Investigation and treatment of hemophilia A with inhibitor of factor VIII (author's transl)].
    Fukutake K, Fujimari M, Ukita M, Kitahara T.
    Rinsho Ketsueki; 1973 Dec 01; 14(0):1393-99. PubMed ID: 4807613
    [No Abstract] [Full Text] [Related]

  • 13. Rapid elimination of a high-titered F VIII inhibitor by high dose recombinant F VIII combined with high dose immunoglobulin infusion.
    Mauz-Korholz C, Korholz D, Gobel U.
    Thromb Haemost; 1997 Aug 01; 78(2):959. PubMed ID: 9268203
    [No Abstract] [Full Text] [Related]

  • 14. How do some haemophiliacs develop inhibitors?
    Vermylen J.
    Haemophilia; 1998 Jul 01; 4(4):538-42. PubMed ID: 9873790
    [Abstract] [Full Text] [Related]

  • 15. Spontaneous disappearance of high titre factor VIII inhibitor 15 years after unsuccessful ITI.
    Thom K, Male C, Falger J, Pabinger I.
    Hamostaseologie; 2009 May 01; 29(2):149-50. PubMed ID: 19404512
    [Abstract] [Full Text] [Related]

  • 16. Immunogenicity and immune tolerance coagulation Factors VIII and IX.
    Rup B.
    Dev Biol (Basel); 2003 May 01; 112():55-9. PubMed ID: 12762504
    [Abstract] [Full Text] [Related]

  • 17. Inhibitor development in one patient and laboratory discrepancies in several families with both mild haemophilia and Arg531Cys mutation.
    Cid AR, Casaña P, Cabrera N, Haya S, Cortina V, Aznar JA.
    Haemophilia; 2007 Mar 01; 13(2):206-8. PubMed ID: 17286776
    [Abstract] [Full Text] [Related]

  • 18. Inhibitor development and successful immune tolerance in an HIV-infected patient with haemophilia A and after immune reconstitution with HAART.
    Kruse-Jarres R, Hadi CM, Leissinger CA.
    Haemophilia; 2007 Nov 01; 13(6):707-11. PubMed ID: 17973846
    [Abstract] [Full Text] [Related]

  • 19. Acquired haemophilia, an unusual cause of severe postpartum haemorrhage.
    Kadir RA, Koh MB, Lee CA, Pasi KJ.
    Br J Obstet Gynaecol; 1997 Jul 01; 104(7):854-6. PubMed ID: 9236657
    [No Abstract] [Full Text] [Related]

  • 20. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.
    Gringeri A, Monzini M, Tagariello G, Scaraggi FA, Mannucci PM, Emoclot15 Study Members.
    Haemophilia; 2006 Mar 01; 12(2):128-32. PubMed ID: 16476086
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.